Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
(NYSE:NVS) Agreement to explore Argo's Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipeline License to an additional Argo siRNA candidate currently in IND-enabling studies Argo will receive an upfront payment of $160 million, an...
Related Questions
How will the $160āÆmillion upfront payment and potential future milestones affect Novartisā (NVS) nearāterm earnings and cash flow?
What strategic implications does the ANGPTL3 siRNA partnership have for Novartis within the competitive dyslipidaemia landscape?
When are the expected key regulatory and clinical milestones for the combination trial and INDāenabling studies, and how might they drive stock volatility?